[Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy].
From March to July 1996, 61 patients with CD4<50/mm(3)began a therapy with protease inhibitors. Increase and maintenance of CD4>100/mm(3) was observed in 39/61 patients with a protective effect for occurrence of AIDS or death. This immunological response was correlated with the duration of the virological response. However, 38% of patients with long-term immunological response never had a undetectable viral load.
Le Moing
V
V
Service des Maladies Infectieuses et Tropicales, Hôpital Bichat--Claude Bernard, Paris.
Eid
Z
Z
Ecobichon
J L
JL
Duval
X
X
Longuet
P
P
Elbim
C
C
Brun-Vezinet
F
F
Leport
C
C
Vilde
J L
JL
D018791:CD4 Lymphocyte Count; D018450:Disease Progression; D005500:Follow-Up Studies; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology* / Q000401:mortality / Q000821:virology; D017320:HIV Protease Inhibitors / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir / Q000276:immunology* / Q000627:therapeutic use*; D019438:Ritonavir / Q000276:immunology* / Q000627:therapeutic use*; D019258:Saquinavir / Q000276:immunology* / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
D017320:HIV Protease Inhibitors; D019469:Indinavir; D019258:Saquinavir; D019438:Ritonavir